CHECKLIST FOR THE SAFEST USE OF DABIGATRAN, RIVAROXABAN & APIXABAN IN ATRIAL FIBRILLATION: INCLUSION & EXCLUSION CRITERIA

被引：0
|
作者：
Leong, Wendy A. [1 ,2 ]
机构：
[1] Burnaby Res Vancouver, Vancouver, BC, Canada
[2] Univ British Columbia Vancouver, Vancouver, BC, Canada
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2014年 / 89卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
180
引用
收藏
页码：E86 / E86
页数：1
相关论文
共 50 条
  • [31] An indirect comparison of dabigatran and rivaroxaban for atrial fibrillation
    Mantha, S.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (03) : 388 - 388
  • [32] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation
    Adeboyeje, Gboyega
    Sylwestrzak, Gosia
    Barron, John J.
    White, Jeff
    Rosenberg, Alan
    Abarca, Jacob
    Crawford, Geoffrey
    Redberg, Rita
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (09): : 968 - 978
  • [33] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [34] Evaluation of Periprocedural Safety and Efficacy of Dabigatran, Rivaroxaban, Apixaban and Edoxaban During Catheter Ablation for Atrial Fibrillation
    Tohoku, Shota
    Hiroshima, Kenichi
    Nagashima, Michio
    Morita, Junji
    Iseda, Takahiro
    Ando, Kengo
    Ando, Kenji
    CIRCULATION, 2016, 134
  • [35] Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran
    Holt, Anders
    Strange, Jarl E.
    Rasmussen, Peter Vibe
    Blanche, Paul
    Nouhravesh, Nina
    Jensen, Mads Hashiba
    Schjerning, Anne-Marie
    Schou, Morten
    Torp-Pedersen, Christian
    Gislason, Gunnar H.
    Hansen, Morten Lock
    McGettigan, Patricia
    Lamberts, Morten
    AMERICAN JOURNAL OF MEDICINE, 2022, 135 (05): : 595 - +
  • [36] Impact of dabigatran, rivaroxaban and apixaban treatment on hemostasis point-of-care testing in patients with atrial fibrillation
    Paniccia, R.
    Marcucci, R.
    Priora, R.
    Poli, D.
    Ahmed, Y.
    Fanciullacci, C.
    Liotta, A. A.
    Abbate, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 394 - 395
  • [37] Anticoagulant effect of dabigatran, rivaroxaban and apixaban treatment on different laboratory hemostasis tests in patients with atrial fibrillation
    Paniccia, R.
    Marcucci, R.
    Priora, R.
    Poli, D.
    Lembo, G.
    Fanciullacci, C.
    Grifoni, E.
    Pazzi, M.
    Liotta, A. A.
    Abbate, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 395 - 395
  • [38] Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
    Staerk, L.
    Gerds, T. A. G.
    Lip, G. Y. H. L.
    Ozenne, B. O.
    Bonde, A. N. B.
    Lamberts, M. L.
    FosboL, E. L. F.
    Torp-Pedersen, C. T. P.
    Gislason, G. G.
    Olesen, J. B. O.
    EUROPEAN HEART JOURNAL, 2017, 38 : 416 - 416
  • [39] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [40] Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
    Staerk, L.
    Gerds, T. A.
    Lip, G. Y. H.
    Ozenne, B.
    Bonde, A. N.
    Lamberts, M.
    Fosbol, E. L.
    Torp-Pedersen, C.
    Gislason, G. H.
    Olesen, J. B.
    JOURNAL OF INTERNAL MEDICINE, 2018, 283 (01) : 45 - 55
12345